Mobile Terminal Based Management of Stroke Secondary Prevention Adminstration Effect Research

Not Applicable

• Conditions: Stroke
• Interventions: Procedure: traditional management; Procedure: website platform management; Procedure: Mobile terminal

• Registration Number: NCT02618265
• Lead Sponsor: Peking University Third Hospital

Brief Summary

The investigators want to verify whether mobile application based on stroke strengthen prevention management is more effective than traditional management model or open stroke management platform. Whole blood-impedance based platelet aggregation(WBA) method and VerifyNow detected by aspirin or clopidogrel responsiveness will provide individualized anti-platelet drug selection. Endpoint event is defined as stroke death or relapse. Primary measure outcomes are change of the stroke recurrence rate and mortality after secondary prevention.

Detailed Description

With high incidence, mortality, morbidity and recurrence rate，stroke has significant impact on national development strategies planning. Improving secondary prevention will strongly promote stroke management in the rapid developing phase of Chinese economy and expansion of health situation. At present lack of high-quality medical resources, low medical permeability cannot remedy extensive prevention failure of stroke. Mobile healthcare is easier to conduct and still in the early stage of explosive growth. This research group has established an open management platform of stroke prevention. And collaborate with Peking University Institute of Information Technology to develop a smart phone application which can be personalized medication reminder, record medication compliance, home blood pressure and blood glucose test results, also can provide doctor-patient communication platform and symptoms alarm. The investigators want to verify whether mobile application based on stroke strengthen prevention management is more effective than traditional management model or open stroke management platform. Whole blood-impedance based platelet aggregation(WBA) method and VerifyNow detected by aspirin or clopidogrel responsiveness will provide individualized anti-platelet drug selection. Control group will be selected from the National Stroke data registration database platform and open platform for stroke prevention. Follow-up period is 2 years. Endpoint event is defined as stroke death or relapse. Primary measure outcomes are change of the stroke recurrence rate and mortality after secondary prevention.

Study Timeline

• Study First Submitted: 2015-09-16
• Status Verified: 2015-11
• Study First Submitted QC: 2015-11-27
• Last Update Submitted: 2015-11-27
• Study First Posted: 2015-12-01
• Last Update Posted: 2015-12-01
• Study Start: 2016-01
• Primary Completion: 2016-12
• Study Completion: 2018-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 400

Inclusion Criteria

• stroke

Read More

Exclusion Criteria

• refusion in research

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
traditional management	traditional management	Stroke received traditional management for secondary prevention administration
website platform management	website platform management	Stroke received website platform management for secondary prevention administration. Website platform management conducts the control and regulation for anti hypertension, statin and antiplatelet therapy to increasing drug compliance.
Mobile terminal	Mobile terminal	Stroke received mobile terminal management for secondary prevention administration, as the same time platelet reactivity modified drug selection was performed. Mobile application management conducts the control and regulation for anti hypertension, statin and antiplatelet therapy to increasing drug compliance.

Primary Outcome Measures

Name	Time	Method
change of the stroke recurrence rate	2 years stroke recurrence rate	After secondary prevention

Secondary Outcome Measures

Name	Time	Method
change of the stroke mortality	2 years stroke mortality	After secondary prevention

Trial Locations

Locations (1)

Peking University Third Hospital; 🇨🇳 Beijing, Beijing, China